SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-334588
Filing Date
2021-11-19
Accepted
2021-11-19 08:30:56
Documents
12
Period of Report
2021-11-17
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d259869d8k.htm   iXBRL 8-K 21472
  Complete submission text file 0001193125-21-334588.txt   142444

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nltx-20211117.xsd EX-101.SCH 2880
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE nltx-20211117_lab.xml EX-101.LAB 18139
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nltx-20211117_pre.xml EX-101.PRE 11400
5 EXTRACTED XBRL INSTANCE DOCUMENT d259869d8k_htm.xml XML 3358
Mailing Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102
Business Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102 206-732-2133
Neoleukin Therapeutics, Inc. (Filer) CIK: 0001404644 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36327 | Film No.: 211426454
SIC: 2834 Pharmaceutical Preparations